

ERRATA

Boikos, C, De Serres G, Lands LC, et al. Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. *Pediatrics*. 2014;134(4):e983

An error occurred in the article by Boikos et al, titled “Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis” published in the October 2014 issue of *Pediatrics* (2014;134(4):e983–991; doi 10.1542/peds.2014-0887). On page e998, the authors inadvertently counted incorrect numbers of study participants reporting the following adverse events following immunization in Table 3: headache, worsening of cough, increased sputum, abdominal pain, muscle aches, nausea, vomiting, eye redness, difficulty breathing and difficulty swallowing. These miscalculations were due to coding errors and were discovered in the course of conducting a secondary analysis using the same data. The major conclusions of the paper remain unchanged and the sub-analyses pertaining to the adverse events following immunization of wheezing and fever are also the same. Furthermore, these corrections do not change any major conclusions reported in this study. The analyses have been re-run and the corrected version of Table 3 is below. The two largest risk ratios now correspond to difficulty breathing and to redness in both eyes, not joint pain and muscle aches as previously reported. The overall risk of reporting at least one minor symptom during follow up is 2.28 times (95% CI 1.87, 2.78) higher in the first month following live-attenuated influenza vaccination compared with the second month, not 1.43 (95% CI 1.22-1.68) as previously reported.

doi:10.1542/peds.2016-2521

TABLE 3 Reported Symptoms by Study Period and Age

Symptom ^a	All Study Participants (n=168)				Days 0-28		
	Days 0-6	Days 0-28	Days 29-56	RR ^b (95% CI)	<9 y old (n = 60)	≥9 y old (n = 108)	RR (95% CI)
Runny Nose	56 (33%)	74 (44%)	28 (17%)	2.64 (1.81, 3.86)	35 (58%)	39 (36%)	1.62 (1.16, 2.25)
Nasal congestion	48 (29%)	67 (40%)	23 (14%)	2.91 (1.91, 4.45)	27 (45%)	40 (37%)	1.22 (0.84, 1.76)
Headache	48 (29%)	56 (33%)	13 (8%)	4.31 (2.45, 7.57)	12 (20%)	44 (41%)	0.49 (0.28, 0.85)
Tiredness	46 (27%)	53 (32%)	11 (7%)	4.82 (2.61, 8.90)	17 (28%)	36 (33%)	0.85 (0.52, 1.38)
Worsening of cough	25 (15%)	46 (27%)	22 (13%)	2.09 (1.32, 3.31)	18 (30%)	28 (30%)	1.16 (0.70, 1.91)
Sore throat	36 (21%)	49 (29%)	11 (7%)	4.45 (2.40, 8.26)	13 (22%)	36 (33%)	0.65 (0.37, 1.13)
Increased sputum	29 (17%)	33 (20%)	5 (3%)	6.6 (2.64, 16.49)	10 (17%)	23 (21%)	0.78 (0.40, 1.53)
Abdominal pain	28 (17%)	34 (20%)	10 (6%)	3.80 (1.94, 7.46)	13 (22%)	21 (19%)	1.11 (0.60, 2.06)
Muscle aches	24 (14%)	29 (17%)	3 (2%)	9.67 (3.00, 31.12)	7 (12%)	22 (20%)	0.57 (0.26, 1.26)
Chills	24 (14%)	26 (15%)	4 (2%)	6.50 (2.31, 18.22)	7 (12%)	19 (18%)	0.66 (0.30, 1.49)
Sleep disturbance	17 (10%)	23 (14%)	6 (4%)	3.83 (1.60, 9.17)	10 (17%)	13 (12%)	1.38 (0.65, 2.97)
Diarrhea	16 (10%)	22 (13%)	5 (3%)	4.40 (1.71, 11.34)	11 (18%)	11 (10%)	1.80 (0.83, 3.90)
Nausea	21 (13%)	22 (13%)	9 (5%)	2.44 (1.15, 5.15)	8 (13%)	14 (13%)	1.03 (0.46, 2.31)
Joint pain	17 (10%)	21 (13%)	2 (1%)	10.50 (2.50, 44.08)	6 (10%)	15 (14%)	0.72 (0.29, 1.76)
Vomiting	15 (9%)	22 (13%)	4 (2%)	5.50 (1.94, 15.62)	12 (20%)	10 (9%)	2.16 (0.99, 4.70)
Redness in both eyes	14 (8%)	15 (9%)	1 (0.6%)	15 (2.00, 112.28)	7 (12%)	8 (7%)	1.58 (0.60, 4.13)
Difficulty breathing	17 (10%)	18 (11%)	1 (0.5%)	18 (2.43, 133.31)	5 (8%)	13 (12%)	0.69 (0.26, 1.85)
Difficulty swallowing	13 (8%)	16 (10%)	2 (1.2%)	8 (1.87, 34.25)	6 (10%)	10 (9%)	1.08 (0.41, 2.83)
Wheezing	13 (8%)	13 (8%)	3 (2%)	4.33 (1.26, 14.93)	6 (10%)	7 (6%)	1.54 (0.54, 4.38)
Facial swelling	10 (6%)	10 (6%)	0	—	4 (7%)	6 (6%)	1.20 (0.35, 4.09)
Fever	59 (35%)	64 (38%)	15 (9%)	4.27 (1.24, 7.18)	27 (45%)	37 (24%)	1.31 (0.90, 1.93)
At least 1 symptom	127 (76%)	148 (88%)	65 (39%)	2.28 (1.87, 2.78)	55 (75%)	93 (76%)	1.06 (0.96, 1.19)

^a Symptom dichotomized as ever/never experience during at-risk and non-at-risk periods.

^b Comparing at-risk versus non-at-risk periods

Number of participants reporting redness in both eyes: 9 on day 0, 2 on day 1, 1 on each day 3, 4, and 6. Also, 9 participants reported facial swelling on day 0 and 1 on day 3.

Boikos, C, De Serres G, Lands LC, et al. Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. *Pediatrics*. 2014;134(4):e983

Pediatrics 2016;138;

DOI: 10.1542/peds.2016-2521 originally published online September 30, 2016;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/138/4/e20162521>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):
Administration/Practice Management
http://www.aappublications.org/cgi/collection/administration:practice_management_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Boikos, C, De Serres G, Lands LC, et al. Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. *Pediatrics*. 2014;134(4):e983

Pediatrics 2016;138;

DOI: 10.1542/peds.2016-2521 originally published online September 30, 2016;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/138/4/e20162521>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

